blog

ARVO 2025: Breakthrough Cross-Attention Network for Glaucoma Detection Glaucoma, a leading cause of irreversible blindness worldwide, has long posed challenges for early detection and accurate diagnosis. However, a groundbreaking innovation unveiled at ARVO 2025 promises to revolutionize glaucoma screening—the Cross-Attention Network (CAN). This cutting-edge deep learning model leverages advanced attention mechanisms to enhance diagnostic precision, […]

# Preservative-Free Glaucoma Drops vs. MIGS: COPHy Insights Glaucoma management continues to evolve, with new treatment options offering improved efficacy and patient comfort. At the recent **Congress on Controversies in Ophthalmology (COPHy)**, experts debated the merits of **preservative-free glaucoma drops** versus **minimally invasive glaucoma surgery (MIGS)**. Both approaches aim to lower intraocular pressure (IOP) while

# Sanoculis Secures CE Mark for Innovative Glaucoma Treatment Device ## Introduction In a significant milestone for ophthalmic innovation, **Sanoculis** has recently obtained the **CE Mark** for its groundbreaking glaucoma treatment device. This regulatory approval paves the way for the commercialization of their cutting-edge technology in **Europe**, offering new hope for patients suffering from this

# Pilocarpine Eye Drops Enhance Results After Kahook Dual Blade Goniotomy ## Introduction Glaucoma is a leading cause of irreversible blindness worldwide, and surgical interventions like the Kahook Dual Blade (KDB) goniotomy have emerged as effective treatments to lower intraocular pressure (IOP). However, recent studies suggest that combining KDB with pilocarpine eye drops can further

# Perfuse Therapeutics to Present PER-001 Glaucoma Implant at ARVO Meeting ## Introduction Perfuse Therapeutics, a pioneering biotech company specializing in innovative ophthalmic treatments, is set to unveil its groundbreaking PER-001 glaucoma implant at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. This highly anticipated presentation marks a significant milestone in

Open Angle Glaucoma Clinical Trials 2025: FDA, EMA, and NICE Approvals Open-angle glaucoma (OAG) remains one of the leading causes of irreversible blindness worldwide. With an aging population and increasing prevalence, the demand for innovative treatments is higher than ever. The year 2025 is poised to be a landmark period for OAG clinical trials, with

Breakthrough Glaucoma Monitoring Device Secures CIHR Commercialization Funding In a significant milestone for ophthalmology and medical technology, a groundbreaking glaucoma monitoring device has secured crucial funding from the Canadian Institutes of Health Research (CIHR) to advance its commercialization. This innovative device promises to revolutionize how glaucoma—a leading cause of irreversible blindness—is monitored and managed, offering

# Evolution of Glaucoma Treatment: Advancements for Patients and Physicians Glaucoma, often referred to as the “silent thief of sight,” is a leading cause of irreversible blindness worldwide. Over the years, the treatment of glaucoma has evolved significantly, offering patients and physicians more effective and less invasive options. From ancient remedies to cutting-edge surgical techniques,

# Top Glaucoma and Retina Trends at ASCRS & ASOA Annual Meetings The ASCRS & ASOA Annual Meetings are among the most anticipated events in ophthalmology, bringing together leading experts to discuss groundbreaking advancements in eye care. This year, the spotlight was on glaucoma and retina treatments, with innovative technologies, surgical techniques, and pharmaceutical developments

Rare PTPRB Gene Linked to Eye and Vein Disorders Recent scientific discoveries have shed light on the role of the PTPRB gene in the development of rare eye and vein disorders. This gene, which encodes a protein tyrosine phosphatase, plays a crucial role in vascular development and maintenance. Mutations in PTPRB have now been linked